Form 4: Surrozen COO Granted 102,900 Stock Options, RSUs

Surrozen, Inc.'s Chief Operating Officer, Charles O. Williams, was granted 102,900 employee stock options and 102,900 restricted stock units.

Summary

• Charles O. Williams, Surrozen's Chief Operating Officer, was granted 102,900 employee stock options on February 17, 2026.
• The options have an exercise price of $24.53 per share and are set to expire on February 16, 2036.
• These stock options will vest over a four-year period in 48 equal monthly installments, commencing from February 1, 2026, contingent upon Mr. Williams' continued service.
• Mr. Williams also received 102,900 Restricted Stock Units (RSUs) on February 17, 2026.
• Each RSU represents a contingent right to receive one share of Surrozen's common stock.
• The RSUs will vest in four equal annual installments, starting on February 1, 2026, also subject to Mr. Williams' continued service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a routine disclosure of executive compensation, which is generally positive for aligning management incentives with shareholder interests, but it does not provide new operational or financial performance data.

Positives

• The equity grants align executive compensation with long-term shareholder value through significant equity ownership.
• The multi-year vesting schedules for both options and RSUs incentivize the Chief Operating Officer's continued service and performance over an extended period.

Future Outlook

The grants include vesting schedules extending to February 2030 for both the stock options and RSUs, indicating an expectation of continued long-term service and contribution from the Chief Operating Officer.

Industry Context

StockSavvy.ai notes that equity grants, such as stock options and restricted stock units, are a common and widely accepted practice in the biotechnology and pharmaceutical industries to attract, retain, and incentivize key executives. This aligns executive interests with long-term company performance, a standard approach in growth-oriented sectors.

Comparison to Industry Standards

• Equity compensation packages for C-suite executives in the biotech sector often include a mix of stock options and RSUs, similar to this grant.
• For instance, executives at comparable early-stage biotech firms like those developing novel therapies (e.g., CRISPR Therapeutics AG or Editas Medicine, Inc. in their earlier stages) frequently receive substantial equity grants tied to multi-year vesting schedules to encourage long-term commitment and align with shareholder value creation.
• The size of the grant for a COO at a company like Surrozen, which is focused on regenerative medicine, appears consistent with industry norms for incentivizing leadership in a high-risk, high-reward sector.

Related Party Transactions

• The grant of stock options and restricted stock units to the Chief Operating Officer is a related party transaction as it involves compensation between the company and an executive.

Stakeholder Impact

• Shareholders: Potential positive impact through better alignment of executive incentives with long-term company performance and shareholder value creation.
• Employees: May signal stability in executive leadership and a commitment to long-term growth within the company.

Next Steps

• The employee stock options will continue to vest in 48 equal monthly installments starting February 1, 2026.
• The restricted stock units will continue to vest in four equal annual installments starting February 1, 2026.

Key Dates

Recommendation

This Form 4 filing is a standard disclosure of executive equity compensation and does not contain information that would fundamentally alter an investment thesis. It reflects routine corporate governance and compensation practices, suggesting no immediate catalyst for a 'buy' or 'sell' decision based solely on this report. Investors should continue to hold and monitor broader company performance and market conditions.

Keywords

Surrozen Inc., SRZN, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, RSUs, Executive Compensation, Equity Grant, Charles O. Williams, Chief Operating Officer